| scholarly article | Q13442814 |
| P50 | author | Taro Kishi | Q57059240 |
| Nakao Iwata | Q83642043 | ||
| Reiji Yoshimura | Q107749594 | ||
| P2093 | author name string | Kazuto Oya | |
| Kiyoshi Fujita | |||
| Yuki Matsuda | |||
| Ikuo Nomura | |||
| Kenji Sakuma | |||
| Yuki Matsui | |||
| Toshihiko Funahashi | |||
| Makoto Okuya | |||
| P2860 | cites work | The clinical relevance of percentage improvements on the PANSS score. | Q51898255 |
| Can Aripiprazole Worsen Psychosis in Schizophrenia? A Meta-Analysis of Double-Blind, Randomized, Controlled Trials. | Q52344472 | ||
| The Positive and Negative Syndrome Scale (PANSS): rationale and standardisation | Q69438858 | ||
| Efficacy and Safety of Brexpiprazole for the Treatment of Acute Schizophrenia: A 6-Week Randomized, Double-Blind, Placebo-Controlled Trial | Q87130550 | ||
| Efficacy and safety of brexpiprazole for the treatment of acute schizophrenia in Japan: A 6-week, randomized, double-blind, placebo-controlled study | Q88724209 | ||
| Industry sponsorship bias in research findings: a network meta-analysis of LDL cholesterol reduction in randomised trials of statins | Q24289041 | ||
| Aripiprazole: from pharmacological profile to clinical use | Q26778312 | ||
| Preferred reporting items for systematic reviews and meta-analyses: the PRISMA statement | Q27860868 | ||
| The preclinical profile of brexpiprazole: what is its clinical relevance for the treatment of psychiatric disorders? | Q38592139 | ||
| Efficacy of brexpiprazole in patients with acute schizophrenia: Review of three randomized, double-blind, placebo-controlled studies | Q38829159 | ||
| Antipsychotic-Induced Dopamine Supersensitivity Psychosis: Pharmacology, Criteria, and Therapy | Q39396657 | ||
| Clozapine eligibility among state hospital patients | Q41018836 | ||
| A multicenter, randomized, double-blind, controlled phase 3 trial of fixed-dose brexpiprazole for the treatment of adults with acute schizophrenia | Q47994149 | ||
| P275 | copyright license | Creative Commons Attribution-NonCommercial 3.0 Unported | Q18810331 |
| P6216 | copyright status | copyrighted | Q50423863 |
| P407 | language of work or name | English | Q1860 |
| P921 | main subject | placebo | Q269829 |
| schizophrenia | Q41112 | ||
| P304 | page(s) | 2519-2530 | |
| P577 | publication date | 2018-10-01 | |
| P1433 | published in | Neuropsychiatric Disease and Treatment | Q15716332 |
| P1476 | title | Comparison of the efficacy and safety of 4 and 2 mg/day brexpiprazole for acute schizophrenia: a meta-analysis of double-blind, randomized placebo-controlled trials | |
| P478 | volume | 14 |
Search more.